FSGS and the Effects of LDL Apheresis

Effect of LDL-Apheresis on Cardiovascular and Renal Outcomes in Focal Segmental Glomerulosclerosis

Protocol Description

Through this investigation, researchers are studying whether the removal of certain cholesterol containing particles from blood of patients with focal segmental glomerulosclerosis (FSGS) via LDL-apheresis may also have beneficial effects relating to inflammation and heart health. FSGS is a rare disease that causes scarring in parts of the kidneys that filter waste materials from blood, allowing protein to leak into the urine, a condition called proteinuria. If the protein leaks for too long, it can lead to kidney failure.

Eligibility Criteria

Patients with FSGS and FSGS recurrence after kidney transplantation who are receiving LDL-apheresis as part of standard of care will be enrolled in the study.
Males and Females: Up to 21 years of age


Study procedures will be done on the same days as LDL apheresis treatments and will consist of blood draws at specific intervals and arterial stiffness measurement, including ultrasound imaging and electrocardiograms, at the beginning and end of the study period.
Visits: None beyond normal scheduled visits for LDL apheresis
Duration: 9 weeks

Status: Enrolling by Invitation

Source(s) of Support

Children’s Hospital Medical Center, Cincinnati
Kaneka Pharma America

Primary Investigator

Michael Moritz, MD

Contact Information

For more information about the study or enrollment, please contact:
Dawn Thomas, RN, MSN, CPN